BCLI vs. SRZN, PLUR, ACHL, SABS, ESLA, INKT, QNCX, CYTH, CRTX, and OKYO
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Surrozen (SRZN), Pluri (PLUR), Achilles Therapeutics (ACHL), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), Quince Therapeutics (QNCX), Cyclo Therapeutics (CYTH), Cortexyme (CRTX), and OKYO Pharma (OKYO). These companies are all part of the "medical" sector.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Surrozen.
Brainstorm Cell Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
In the previous week, Brainstorm Cell Therapeutics had 8 more articles in the media than Surrozen. MarketBeat recorded 9 mentions for Brainstorm Cell Therapeutics and 1 mentions for Surrozen. Brainstorm Cell Therapeutics' average media sentiment score of 0.67 beat Surrozen's score of 0.00 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.
14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 5.5% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 43.5% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Brainstorm Cell Therapeutics' return on equity of 0.00% beat Surrozen's return on equity.
Brainstorm Cell Therapeutics received 287 more outperform votes than Surrozen when rated by MarketBeat users. Likewise, 63.74% of users gave Brainstorm Cell Therapeutics an outperform vote while only 16.67% of users gave Surrozen an outperform vote.
Summary
Brainstorm Cell Therapeutics beats Surrozen on 6 of the 11 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
